TNFSF10 and neoplasm: The sensitivity of tumor cells to Apo2L/TRAIL makes it attractive as a potential anticancer therapeutic, but drug development efforts have been hampered by literature reports of hepatotoxicity of non-optimized versions of Apo2L/TRAIL23 and by observations of hepatotoxicity as described in this report, as well as by an apparent lack of clinical efficacy.18